Each patient needs to weigh the benefits and risks of genetic testing for melanoma and have someone who can take the time to explain everything, including insurance risks, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.
Each patient needs to weigh the benefits and risks of genetic testing for melanoma and have someone who can take the time to explain everything, including insurance risks, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.
Transcript
After a patient gets a genetic test to understand their risk for developing melanoma, what should the next steps be for them?
It needs to be tailored for the individual. I send all of my patients who are candidates for testing to a genetic counselor, because I feel like they can spend the time to sit with them—they'll spend an hour or 2 hours sometimes—discussing the pros and the cons of getting the genetic testing, and whether or not that's something they want to go through at this time or not. They'll spend time finding out if their insurance will cover it after the testing or not, or if they're going to have to pay out of pocket. They spend the time really going through deeply through their pedigree, so that they can identify not just the melanoma genes, but let's say they had breast cancer or colon cancer, they want to put the genes that are responsible for those sort of patterns of cancer in the panel that gets tested, and they can help to identify those specific genes that need to be for sure included in the panel. That takes a lot of time.
I think that the patient is best served by having a person who can devote that time to doing a really thorough job with that and talking about the risks of insurance. In the United States, we've got GINA, the Genetic Information Nondiscrimination Act. Most states also have a nondiscrimination act. Those are very important to make sure that if you do get genetic testing, that you don't have to worry about your health insurance or your employment. It's illegal to fire you or cancel your health insurance. You can't have that happen. But you can have a problem getting life insurance or disability insurance, because those are considered more of the luxury items. They don't fall under the GINA or the nondiscrimination act for the state.
You need to make sure that you know those risks and that the knowledge that you're getting, is going to be worth it. I think that the next step is to really consider that, and to have somebody that can sit and talk to you about it and make sure that you understand what the real risks and benefits are. And I haven't talked about the benefits, but I think those are just as important. And I do think in many cases, the benefits do outweigh the risks there.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More